Spyre Just Dropped the Best Report Card in UC's Hottest Drug Class
Spyre's experimental antibody SPY002 just posted what may be the strongest histologic improvement data in the anti-TL1A class for ulcerative colitis. Analysts are pounding the table with price targets up to $115, but the real test is still a year away.
Imagine your gut lining is a wall. In ulcerative colitis, that wall is under constant siege: inflamed, ulcerated, crumbling from the inside. Now imagine a drug that doesn't just ease the symptoms but actually starts repairing the brickwork. That's what Spyre Therapeutics says its experimental antibody just did, and the numbers backing up that claim have Wall Street reaching for superlatives.
On June 15, 2026, Spyre reported Phase 2 results for SPY002 in moderate-to-severe ulcerative colitis (UC). The drug hit its primary endpoint with a 10.7-point mean reduction in the Robarts Histopathology Index (RHI) at 12 weeks, with a p-value of less than 0.0001. If that sounds like alphabet soup, stick with me: it matters a lot more than it looks.
A Scoring System That Actually Means Something
The RHI is a 0-to-33 scale that pathologists use to grade how bad UC looks under a microscope. Zero means clean tissue. Thirty-three means your gut lining is in serious trouble. It scores things like inflammatory cell infiltration, neutrophil presence, and erosions or ulceration.
Most patients entering these trials have baseline scores somewhere in the mid-teens to low twenties. So a 10.7-point drop isn't just statistically significant; it represents a dramatic shift in what the tissue actually looks like. International consensus guidelines define a "meaningful histologic improvement" as a 7-point reduction or greater. SPY002 blew past that threshold by nearly 4 points.
To put it in sports terms: the bar for making the team was a 7. Spyre scored a 10.7.
The Rest of the Report Card Looks Good, Too
Histology was the headline, but SPY002 delivered across the board. At week 12, 33% of patients hit clinical remission and 42% showed endoscopic improvement (visible healing when doctors looked inside with a scope). The modified Mayo Score, a composite measure of UC severity, dropped by 3.7 points from baseline.
Spyre called these results "among the highest reported in UC" for the anti-TL1A class. Bold claim? Sure. But context supports it. In the same trial program (called SKYLINE), Spyre's other antibody, SPY001, posted a 9.2-point RHI reduction. SPY002 beat its sibling by a point and a half on the primary endpoint.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Safety looked clean, too. Twenty patients experienced treatment-emergent adverse events during induction. There were two serious adverse events, but neither was judged to be drug-related: one was a UC flare requiring hospitalization, and the other was worsening heart failure in a patient who already had the condition.
What Exactly Is TL1A, and Why Should You Care?
TL1A is a protein in the TNF superfamily that acts like a fire alarm stuck in the "on" position. It binds to a receptor called DR3 on immune cells and tells them to keep attacking, keep inflaming, keep damaging tissue. In IBD patients, TL1A levels are elevated, and genetic variants in the TL1A gene are linked to higher disease risk.
SPY002 is a fully human antibody that grabs onto TL1A with extremely high affinity (think of it as a lock that fits only one key) and blocks it from reaching DR3. No signal, no inflammatory cascade. The antibody is also engineered with an extended half-life, meaning patients could potentially receive maintenance doses as infrequently as every three to six months. For a disease that often requires biweekly or monthly injections, that's a game-changer for patient quality of life.
A Crowded Party, and Spyre Showed Up Loud
UC is a roughly $9 billion global market growing at 5-8% annually, and the guest list of competitors reads like a pharma all-star roster. AbbVie's Skyrizi, J&J's Tremfya, Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Entyvio: the biggest companies in the world are fighting for share in moderate-to-severe UC.
The newest wave of competition is especially fierce. J&J's icotrokinra, the first oral IL-23 receptor inhibitor, was approved in March 2026 for moderate-to-severe plaque psoriasis, with UC studies still ongoing. New JAK inhibitors are launching in Asia. Biosimilars have captured roughly 20% of the biologics segment, squeezing margins on older drugs.
So why does a mid-cap biotech's Phase 2 readout matter in this crowd? Because TL1A is emerging as one of the most compelling new targets in IBD, and Spyre is positioning itself as the class leader. The company isn't just running monotherapy trials, either. Its SKYLINE platform is designed to test pairwise combinations of its three core antibodies (anti-TL1A, anti-α4β7, anti-IL-23), which could unlock deeper responses than any single drug alone.
Analysts Are Buying What Spyre Is Selling
The Street's reaction was unambiguous. Multiple firms reiterated Buy or Outperform ratings after the data dropped. Guggenheim maintained its Buy with a $115 price target. Stifel kept its Buy rating at $92. Leerink held Outperform, and Mizuho did the same.
Analysts pointed to the TL1A mechanism being "clinically de-risked" within Spyre's portfolio, supporting higher probabilities of success and bigger peak-sales estimates.
BTIG, which had previously raised its target to $98 after strong SPY001 data, noted that SPY002's performance reinforces conviction in TL1A-based regimens and the broader combination strategy.
The Caveats You Should Actually Read
Before you get swept up in the enthusiasm, some important fine print. This was Part A of a Phase 2 trial, and it was open-label, meaning there was no placebo group for comparison. Patients and doctors both knew what drug was being given. That matters because placebo response rates in UC trials can be surprisingly high.
Placebo-controlled data from Part B aren't expected until 2027. That's the real test. Open-label results are a promising signal, not proof. Spyre also hasn't disclosed granular details like baseline RHI scores or the proportion of patients achieving histologic remission (RHI ≤3), which would help gauge just how deep these responses go.
Then there's execution risk. Spyre is a company that was essentially reborn in 2023 when a struggling rare-disease biotech called Aeglea acquired a private IBD-focused antibody shop and rebranded. It's raised significant capital since (including a reported $463.5 million in April 2026), but translating Phase 2 signals into Phase 3 success, regulatory approval, and commercial launch against entrenched pharma giants is a long, expensive road.
The Bottom Line
Spyre's SPY002 just posted what may be the strongest histologic data any anti-TL1A antibody has produced in UC. In a disease where microscopic healing increasingly predicts long-term outcomes, that's not a trivial achievement. The combination strategy, the extended dosing interval, and the analyst enthusiasm all make for a compelling narrative.
But narrative isn't data, and open-label isn't placebo-controlled. The next 12 to 18 months will tell us whether Spyre's wall-repair job holds up under scrutiny. For now, the bricks look solid.
5 min read
Adaptive Biotech Is Breaking Up With Itself
Adaptive Biotechnologies is splitting its profitable cancer diagnostics business from its early-stage drug discovery platform into two separate companies. The move follows a growing industry trend of corporate breakups designed to let fundamentally different businesses attract the right investors.
